Novo Nordisk Faces Boardroom Shake-Up Amid Investor Concerns

Shares of pharmaceutical giant Novo Nordisk dipped approximately 3% on Wednesday, continuing the decline from the previous day. The drop followed a significant proposal for a board restructuring by the firm’s leading investor, the Novo Nordisk Foundation. The non-profit entity announced that current chair Helge Lund and six other board members would be resigning next month over disagreements with the foundation regarding the company's direction.

The Novo Nordisk Foundation is set to appoint former company CEO Lars Rebien Sorensen as the new chairperson, a decision aimed at navigating the company through strategic changes. The foundation has also put forward six new candidates for board positions. This upheaval has contributed to Novo's shares falling by about 45% this year, resulting in a $10 billion loss in market value in just two days.

Market analysts expressed surprise at both the timing and scope of this governance shift, which follows closely after the appointment of a new CEO. Analysts suggest the move seeks to better align board priorities with Novo Nordisk's recent strategy to enhance consumer engagement and focus on the U.S. market. Meanwhile, concerns over pricing talks in the U.S. and competition from Eli Lilly in the weight-loss drug sector continue to stir investor unease.